Outlook Therapeutics, Inc. (OTLK): Price and Financial Metrics

Outlook Therapeutics® to Present at the SVB Securities Global Biopharma Conference

– Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics to present on Tuesday, February 14th at 4:20 PM ET –ISELIN, N.J., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics, will present at the SVB Securi

Yahoo | February 7, 2023

Outlook draws bullish views at Cantor on potential FDA nod for lead asset

• Cantor Fitzgerald launched its coverage on Outlook Therapeutics (NASDAQ:OTLK) on Monday with an Overweight recommendation and a 12-month target of $4 per share, expecting the biotech to win the FDA nod for its lead candidate, ONS-5010.
• "We'd be buyers of the name ahead of the summer PDUFA action date," the analyst Kristen Kluska wrote, referring to the FDA action date on Aug. 29 assigned for the company's marketing application for ONS-5010 (Lytenava) in wet age-related macular degeneration (wAMD).
• The analyst explains that Lytenava is an ophthalmic formulation of Roch...

  Seeking Alpha | February 6, 2023

Outlook Therapeutics® Strengthens Medical Affairs and Commercial Expertise with Appointments of Surendra Sharma, MD, Senior Vice President of Medical Affairs and Glen Olsheim, Executive Director of Commercial Excellence

Dr. Sharma and Mr. Olsheim bring more than 30 years of combined experience in the global pharmaceutical and biotechnology industry from their various roles launching and commercializing ophthalmic productsISELIN, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced the appointments of Surendra Sharma,

Yahoo | January 19, 2023

JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th

JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2023 Companies to Watch Event, January 17-19, 2023.

Yahoo | January 11, 2023

Outlook Therapeutics® to Present at the Virtual Investor 2023 Companies to Watch Event

Live video webcast presentation on Tuesday, January 17th at 11:00 AM ETISELIN, N.J., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics will present at the Virtual Investor 2023 Companies to Watch Event on Tuesday, January 17,

Yahoo | January 9, 2023